Czechowicz lab at Stanford Promising research needs continued support to answer the next question. A laboratory finding may need testing in more models. A screening study may need years of follow-up. An approach ready for a clinical study needs the...
Directory
Peter Kurre
Director of the Pediatric Comprehensive Bone Marrow Failure Center | MD | Philadelphia, USA
With extended training in pediatric hematology, oncology and stem cell transplantation, Dr. Kurre’s clinical work is focused on children with hematopoiesis failure (i.e., bone marrow failure) across a wide spectrum of inherited and acquired conditions that lead to loss of blood formation. As a physician-scientist, his clinical and scientific goals are directed at improving our understanding and broadening our treatment options for patients with bone marrow failure.
Dr. Kurre’s clinical interests focus on diagnosis and treatment of bone marrow failure, specifically on improving diagnostic and therapeutic capabilities. Along with colleagues at other institutions, he is spearheading efforts to leverage molecular technologies toward the development of tests that improve diagnostic certainty and timeliness of genetic hematopoiesis failure conditions. Dr. Kurre’s laboratory has longstanding expertise in Fanconi anemia (FA), a rare inherited genetic condition with prominent hematologic complications. The long-term goal is to improve our understanding of the progressive hematopoietic failure that occurs in patients with FA. His other lab projects are focused on stem cell regulation by trafficking of extracellular vesicles in the bone marrow microenvironment.
FA Research Projects
The Latest
News & Events
How can we prevent cancer in people with FA? How can treatments become safer? At the 2026 FA Scientific Symposium in Phoenix, researchers shared progress toward answering these questions, alongside work to protect blood-forming cells and better understand the broader effects of FA. Some approaches are entering clinical studies. Others are helping researchers decide which ideas deserve further testing.
More than four decades ago, Lynn Frohnmayer was a mother searching for answers after learning that three of her five children had Fanconi anemia. There was no roadmap and no established network of families or experts. Information was scarce, treatments were limited, and the future her family had been given was devastating.